ATE165598T1 - Heteroatom-substituierte liganden und metallkomplexe davon - Google Patents

Heteroatom-substituierte liganden und metallkomplexe davon

Info

Publication number
ATE165598T1
ATE165598T1 AT94108968T AT94108968T ATE165598T1 AT E165598 T1 ATE165598 T1 AT E165598T1 AT 94108968 T AT94108968 T AT 94108968T AT 94108968 T AT94108968 T AT 94108968T AT E165598 T1 ATE165598 T1 AT E165598T1
Authority
AT
Austria
Prior art keywords
metal complexes
heteroatom substituted
substituted ligands
heteroatom
complexes
Prior art date
Application number
AT94108968T
Other languages
English (en)
Inventor
Kondareddiar Ramalingam
Natarajan Raju
Original Assignee
Bracco Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22141146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE165598(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bracco Int Bv filed Critical Bracco Int Bv
Application granted granted Critical
Publication of ATE165598T1 publication Critical patent/ATE165598T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/62—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with triarylmethyl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C07D307/71—Nitro radicals attached in position 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/38—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT94108968T 1993-06-15 1994-06-10 Heteroatom-substituierte liganden und metallkomplexe davon ATE165598T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7798193A 1993-06-15 1993-06-15

Publications (1)

Publication Number Publication Date
ATE165598T1 true ATE165598T1 (de) 1998-05-15

Family

ID=22141146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94108968T ATE165598T1 (de) 1993-06-15 1994-06-10 Heteroatom-substituierte liganden und metallkomplexe davon

Country Status (19)

Country Link
US (5) US5608110A (de)
EP (1) EP0629617B2 (de)
JP (1) JP3835831B2 (de)
KR (1) KR100346795B1 (de)
CN (1) CN1055685C (de)
AT (1) ATE165598T1 (de)
AU (1) AU678001B2 (de)
CA (1) CA2125895C (de)
CZ (1) CZ295519B6 (de)
DE (1) DE69409870T3 (de)
DK (1) DK0629617T3 (de)
ES (1) ES2115805T3 (de)
FI (1) FI942795A7 (de)
HU (1) HU9401777D0 (de)
IL (1) IL109925A (de)
NO (1) NO305078B1 (de)
PL (1) PL303843A1 (de)
RU (1) RU94022254A (de)
ZA (1) ZA944201B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359120B1 (en) * 1991-10-29 2002-03-19 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia-localizing moiety
EP0663900B1 (de) * 1992-10-08 1999-09-22 Nycomed Amersham PLC Metall-oxim chelate zur verwendung als röntgenpharmazeutische wirkstoffe
CA2163232A1 (en) * 1993-05-20 1994-12-08 Robert C. Brasch Macromolecular contrast media for mr imaging
CA2168652A1 (en) * 1993-08-04 1995-02-16 Colin Mill Archer Radiometal complexes that localise in hypoxic tissue
IL111592A0 (en) * 1993-12-14 1995-01-24 Bracco Int Bv Stable multilayer lyophile
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US5632969A (en) * 1994-10-13 1997-05-27 Merck & Co., Inc. N3 S2 chelating ligands optionally radiolabelled with Tc or Re, useful for diagnostic or therapeutic applications
WO1998033935A1 (en) * 1997-01-31 1998-08-06 The University Of Alberta Method for detecting exogenous gene expression
US6004529A (en) 1997-04-11 1999-12-21 Nycomed Imaging As Chelating agents
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
EP1772453A1 (de) * 1997-11-07 2007-04-11 Pharmacia & Upjohn Company LLC Verfahren zur Herstellung von Oxazolidinonen
CA2332277A1 (en) * 1998-05-15 1999-11-25 Nycomed Amersham Plc Labelled glutamine and lysine analogues
JP3519302B2 (ja) 1999-02-09 2004-04-12 株式会社東海理化電機製作所 ウエビング巻取装置用プリテンショナー
US6465785B1 (en) * 2000-05-05 2002-10-15 Infrared Solutions, Inc. Apparatus and method for compensating for pixel non-uniformity in a bolometer
US7109167B2 (en) 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US20050074402A1 (en) * 2000-10-19 2005-04-07 Aldo Cagnolini Radiopharmaceutical formulations
US7422733B2 (en) * 2000-11-29 2008-09-09 Bracco International B.V. Linkable sialyl Lewis X analogs
US6384232B1 (en) 2001-03-27 2002-05-07 Bracco International B.V. Methods of synthesizing heteroatom-bearing ligands and intermediate used thereof
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AU2003278807A1 (en) * 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
AU2003224917A1 (en) * 2002-04-11 2003-10-27 Carbomer Diabetes imaging probes
DE60325766D1 (de) * 2002-09-25 2009-02-26 Daiso Co Ltd Verfahren zur Herstellung von Glycidylphthalimide
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
US20050232924A1 (en) * 2003-11-18 2005-10-20 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2006039505A2 (en) 2004-09-30 2006-04-13 Molecular Devices Corporation Luminescent lanthanide complexes
KR100675356B1 (ko) * 2005-04-29 2007-02-01 경희대학교 산학협력단 액체 또는 초임계상태의 유체를 이용하여 금속이온 및금속산화물을 추출하는 금속추출에 사용되는 신규한 아미드화합물을 포함하는 킬레이트제와 상기 킬레이트제를이용한 금속추출방법 및 금속추출시스템
AU2007233155B2 (en) 2006-03-29 2012-04-26 Scitech Development Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
PL2117571T3 (pl) * 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy
CN101558081B (zh) 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
GB0804406D0 (en) * 2008-03-10 2008-04-16 Univ Zuerich Metal complexes
EP2147684A1 (de) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Selektiv gegen Metallproteasen wirkende Diagnosemittel
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
FR2989085A1 (fr) * 2012-04-05 2013-10-11 Commissariat Energie Atomique Radiotraceurs, procedes de preparation et applications
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
EP3322716B1 (de) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-spezifische einfänger und verfahren zur verwendung
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
WO2017137477A1 (en) 2016-02-09 2017-08-17 Bracco Suisse Sa A recombinant chimeric protein for selectins targeting
EP3440101B1 (de) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-spezifische einfänger, zusammensetzungen und verfahren zur verwendung und herstellung davon
US9643939B1 (en) 2016-04-18 2017-05-09 Optimus Drugs Private Limited Process for the preparation of linezolid
USRE47606E1 (en) 2016-04-21 2019-09-17 Optimus Drugs Private Limited Process for the preparation of linezolid
EP4086250B1 (de) 2016-07-06 2024-12-11 The Regents Of The University Of Michigan Multifunktionale inhibitoren von biologischen mek/pi3k und mtor/mek/pi3k pfaden und therapeutische verfahren unter verwendung derselben
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3535278A4 (de) 2016-11-01 2020-06-24 Ohio State Innovation Foundation Verfahren zur jodierung von biomolekülen
CN109890483B (zh) * 2016-11-09 2022-03-01 株式会社可乐丽 氧吸收剂
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
KR102083180B1 (ko) 2017-11-09 2020-03-02 서울대학교산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
WO2019093699A1 (ko) * 2017-11-09 2019-05-16 서울대학교 산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
CN112041293B (zh) * 2018-04-19 2023-10-20 株式会社可乐丽 含不饱和双键化合物、使用了该化合物的氧吸收剂、以及树脂组合物
IL271681A (en) 2018-07-18 2020-01-30 Vyripharm Entpr Llc Systems and methods for integrated and comprehensive management of cannabis products
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US20200291391A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
EP3972646A4 (de) 2019-05-20 2023-06-14 Ohio State Innovation Foundation Apohämoglobin-haptoglobin-komplexe und verfahren zur verwendung davon
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
CA3227425A1 (en) 2021-07-26 2023-02-02 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
CN114907562B (zh) * 2022-01-29 2023-08-18 华东理工大学 β-内酰胺单体的合成及聚合方法
WO2024258974A1 (en) * 2023-06-12 2024-12-19 Regents Of The University Of Minnesota Ligands and complexes and uses thereof
WO2025245032A1 (en) 2024-05-20 2025-11-27 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369121A (en) * 1966-04-06 1968-02-13 Squibb & Sons Inc Radioactive package and container therefor
US3920995A (en) * 1973-05-04 1975-11-18 Squibb & Sons Inc Radioactive material generator
US4071613A (en) * 1976-02-26 1978-01-31 Abbott Laboratories Stabilized alcohol solution of reducing salt formulations for use in preparing radioisotope labeled scanning agents: liver scanning technetium-99m colloid and method of preparation
FR2418648A1 (fr) * 1978-03-02 1979-09-28 Radiochemical Centre Ltd Procede et recipient pour la preparation d'agents de diagnostic renfermant un isotope du technetium
US4193979A (en) * 1978-05-22 1980-03-18 G. D. Searle & Co. Sodium 3-[[[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-amino]carbonyl]-2-pyridinecarboxylic acid and related compounds labeled with technetium-99m
US4272503A (en) * 1978-05-25 1981-06-09 New England Nuclear Corporation Reductant composition for technetium-99m and method for making technetium-99m labelled ligands
US4363793A (en) * 1979-08-30 1982-12-14 State University Of New York Diagnostic radiopharmaceuticals for localization in target tissues exhibiting a regional pH shift relative to surrounding tissues
GB2093451B (en) * 1981-02-24 1984-10-31 May & Baker Ltd Nitroimidazole derivatives
US4431626A (en) * 1981-05-27 1984-02-14 The Regents Of The University Of California Tc-99m Labeled carrier for imaging
US4462992A (en) * 1982-02-08 1984-07-31 Research Corporation Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof
US4444690A (en) * 1982-02-25 1984-04-24 University Patents, Inc. Technetium chelates
US4758682A (en) * 1983-03-17 1988-07-19 California Institute Of Technology Homogeneous coordination compounds as oxidation catalysts
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4638051A (en) * 1984-04-30 1987-01-20 The Johns Hopkins University Brain imaging radiopharmaceuticals
US4980147A (en) * 1984-06-25 1990-12-25 University Of Utah Research Foundation Radiolabeled technetium chelates for use in renal function determinations
GB8426845D0 (en) * 1984-10-24 1984-11-28 Amersham Int Plc Complexes of technetium-99m
JPS61103841A (ja) * 1984-10-26 1986-05-22 Nippon Mejifuijitsukusu Kk 放射性テクネチウム標識に供する安定な塩化第一スズ組成物
DE3687467T2 (de) * 1985-03-11 1993-04-29 Amersham Int Plc Komplexe von technetium-99m mit propylen-amin-oximen.
US5187264A (en) * 1986-05-28 1993-02-16 Mallinckrodt Medical, Inc. Technetium chelates to be used for determining the renal function
ATE52516T1 (de) * 1986-05-28 1990-05-15 Mallinckrodt Inc Technetiumchelate fuer die bestimmung der nierenfunktion.
DE3728599A1 (de) * 1986-12-10 1988-06-23 Hoechst Ag Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz
US5164175A (en) * 1986-12-10 1992-11-17 Hoechst Aktiengesellschaft Diagnostic aid containing an organ-specific substance labeled with technetium-99m
US5091514A (en) * 1987-03-26 1992-02-25 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
US4871836A (en) * 1987-10-13 1989-10-03 E. R. Squibb & Sons, Inc. Boronic acid adducts of rhenium and radioactive isotopes of rhenium dioxime complexes
EP0322876A3 (de) * 1987-12-29 1990-09-05 Nihon Medi-Physics Co., Ltd. Chelierende Verbindungen und deren Verwendung
WO1989010759A1 (en) * 1988-04-29 1989-11-16 Mallinckrodt, Inc. Diaminedithiol chelating agents for radiopharmaceuticals
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5075099A (en) * 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US4925650A (en) * 1988-11-16 1990-05-15 Mallinckrodt, Inc. Technetium -99m complex for examining the renal function
US5026829A (en) * 1989-01-23 1991-06-25 University Of Cincinnati Cyclo substituted propyleneamine oxime and its use as a brain imaging agent
US4895960A (en) * 1989-01-23 1990-01-23 University Of Cincinnati Cyclo substituted propyleneamine oxime and its use as a brain imaging agent
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
CN1022562C (zh) * 1989-04-08 1993-10-27 中国人民解放军第二军医大学 一种消瘤药——甲硝唑氨酸的合成方法
US5101041A (en) * 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
US5164176A (en) * 1989-06-16 1992-11-17 Neorx Corporation Radionuclide metal chelates for the radiolabeling of proteins
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
CA2034042C (en) * 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
JPH06501450A (ja) * 1990-06-01 1994-02-17 インスティトゥート　フュア　ディアグノスティックフォルシュング　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　アン　デア　フライエン　ウニヴェルジテート　ベルリン シクロペンタジエニルカルボニル―９９ｍＴｃ錯体、その製造法および診断学への該化合物の使用
DE4025788C2 (de) * 1990-08-10 1994-04-14 Diagnostikforschung Inst Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung sowie deren Verwendung in Diagnostik und Therapie
US5037631A (en) * 1990-10-29 1991-08-06 Mallinckrodt Medical, Inc. Technetium-99M complex for examinating the renal function
US5104638A (en) * 1990-10-29 1992-04-14 Mallinckrodt Medical, Inc. Method of making a radiopharmaceutical complex from a kit
US5116598A (en) * 1990-10-29 1992-05-26 Mallinckrodt Medical, Inc. N4 technetium-99 m complexes for use as radiopharmaceuticals
GB9028105D0 (en) * 1990-12-27 1991-02-13 Erba Carlo Spa Process for the preparation of substituted benzofuran derivatives
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4107570A1 (de) * 1991-03-07 1992-11-19 Diagnostikforschung Inst Chelate, deren metallkomplexe sowie ihre verwendung in diagnostik und therapie
DE4107571A1 (de) * 1991-03-07 1992-11-19 Diagnostikforschung Inst Amid-chelate, deren metallkomplexe sowie ihre verwendung in diagnostik und therapie
GB9113487D0 (en) * 1991-06-21 1991-08-07 Amersham Int Plc Agents for hypoxic cells
US5385719A (en) * 1991-09-24 1995-01-31 Unger; Evan C. Copolymers and their use as contrast agents in magnetic resonance imaging and in other applications
NZ244613A (en) * 1991-10-29 1996-05-28 Bracco International B V Subst A ligand containing a hypoxia-localising moiety, preparation thereof; a kit (optionally multivial) for preparing a metal complex containing the ligand
EP0663900B1 (de) * 1992-10-08 1999-09-22 Nycomed Amersham PLC Metall-oxim chelate zur verwendung als röntgenpharmazeutische wirkstoffe
EP0618191A1 (de) * 1993-04-02 1994-10-05 AMERSHAM INTERNATIONAL plc Metall-chelatierende Verbindungen

Also Published As

Publication number Publication date
CZ145594A3 (en) 1995-05-17
FI942795L (fi) 1994-12-16
JPH0789922A (ja) 1995-04-04
FI942795A0 (fi) 1994-06-13
US5627286A (en) 1997-05-06
CA2125895A1 (en) 1994-12-16
EP0629617B2 (de) 2007-09-26
US5665329A (en) 1997-09-09
DE69409870T2 (de) 1998-12-10
KR100346795B1 (ko) 2002-11-29
CN1055685C (zh) 2000-08-23
US5608110A (en) 1997-03-04
JP3835831B2 (ja) 2006-10-18
CZ295519B6 (cs) 2005-08-17
IL109925A0 (en) 1994-10-07
AU678001B2 (en) 1997-05-15
NO942231L (no) 1994-12-16
RU94022254A (ru) 1996-04-20
NO942231D0 (no) 1994-06-14
ZA944201B (en) 1995-02-08
EP0629617A1 (de) 1994-12-21
CA2125895C (en) 2000-03-14
KR950000671A (ko) 1995-01-03
DE69409870T3 (de) 2008-03-13
IL109925A (en) 2005-12-18
HU9401777D0 (en) 1994-09-28
PL303843A1 (en) 1994-12-27
AU6467294A (en) 1994-12-22
US5656254A (en) 1997-08-12
DE69409870D1 (de) 1998-06-04
DK0629617T3 (da) 1998-10-07
ES2115805T3 (es) 1998-07-01
US5741912A (en) 1998-04-21
NO305078B1 (no) 1999-03-29
FI942795A7 (fi) 1994-12-16
EP0629617B1 (de) 1998-04-29
CN1099388A (zh) 1995-03-01

Similar Documents

Publication Publication Date Title
ATE165598T1 (de) Heteroatom-substituierte liganden und metallkomplexe davon
FI946157L (fi) Polyaminoituja ligandeja ja niiden metallikomplekseja
FI891310A7 (fi) Piisilloitettuja siirtymämetalliyhdisteitä
ATE156838T1 (de) Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren 5-alpha-reduktases
DE68916345D1 (de) Thermit-Überzug.
DE68906740D1 (de) Metallische zusammensetzung enthaltend zinkoxyd-whisker.
DE68908273D1 (de) Metal radionukleid-chelatverbindungen mit verbesserter chelatierungskinetik.
FI960849L (fi) Metallikomplekseja sisältäviä farmaseuttisia koostumuksia
ATE84537T1 (de) Neue titankatalysatoren.
ATE158300T1 (de) Neue 7-beta-substituierte-4-aza-5-alpha-cholestan-on n als inhibitoren 5-alpha-reduktases
DE69114986D1 (de) Eine Phosphino-Binapthyl-Verbindung und Übergangsmetall-Komplexe davon.
NO305030B1 (no) FremgangsmÕte for fremstilling av overgangsmetallkomplekser med monosubstituerte syklopentadienyl-ligander
FI932035A0 (fi) Tricykliska foereningar innehaollande heteroatomer
BR8401326A (pt) Corpo de metal sinterizado provido de ao menos uma endentacao
FI943452L (fi) Organosiloksaanisidotut transitiometallikompleksit
ES2099900T3 (es) Procedimiento para la preparacion de complejos con metales de derivados de n-beta-hidroxialquil-tri-n-carboxialquil-1,4,7,10-tetraaza-ciclododecanos y de n-beta-hidroxialquil-tri-n-carboxialquil-1,4,8,11-tetraaza-ciclotetradecanos.
DE69129446D1 (de) Bestimmung der Zusammensetzung von Metallschmelzen
DE3887388D1 (de) Metall-Chelat-Verbindung und härtbares Anstrichmittel davon.
DE58908552D1 (de) Übergangsmetallkomplexe.
DE69200351D1 (de) Verfahren zur Direktnitridierung von Metallen mit niedrigem Schmelzpunkt.
DE3685284D1 (de) Chlorieren von eisenhaltigen metallstoffen.
NO892189D0 (no) Trijodbenzenforbindelser og kontrastmidler for radiografiinneholdende disse.
DK472085D0 (da) Metalcomplexer af bis-indolforbindelser
FR2706023B1 (fr) Programmeur analogique amélioré pour fours.
KR890013197A (ko) 함크롬 용철의 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee